These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 36986246)

  • 1. Anti-Inflammatory Effects of Lipid-Lowering Drugs and Supplements-A Narrative Review.
    Zivkovic S; Maric G; Cvetinovic N; Lepojevic-Stefanovic D; Bozic Cvijan B
    Nutrients; 2023 Mar; 15(6):. PubMed ID: 36986246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefits and drawbacks of statins and non-statin lipid lowering agents in carotid artery disease.
    Paraskevas KI; Gloviczki P; Antignani PL; Comerota AJ; Dardik A; Davies AH; Eckstein HH; Faggioli G; Fernandes E Fernandes J; Fraedrich G; Geroulakos G; Golledge J; Gupta A; Gurevich VS; Jawien A; Jezovnik MK; Kakkos SK; Knoflach M; Lanza G; Liapis CD; Loftus IM; Mansilha A; Nicolaides AN; Pini R; Poredos P; Proczka RM; Ricco JB; Rundek T; Saba L; Schlachetzki F; Silvestrini M; Spinelli F; Stilo F; Suri JS; Svetlikov AV; Zeebregts CJ; Chaturvedi S; Veith FJ; Mikhailidis DP
    Prog Cardiovasc Dis; 2022; 73():41-47. PubMed ID: 35605696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do we need new lipid-lowering agents in the era of PCSK9 inhibitors? Recent advances.
    Atar D; Langslet G; Tonstad S
    Kardiol Pol; 2022; 80(7-8):741-749. PubMed ID: 35521719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease.
    Katsiki N; Mikhailidis DP; Banach M
    Expert Opin Pharmacother; 2019 Nov; 20(16):2007-2017. PubMed ID: 31344332
    [No Abstract]   [Full Text] [Related]  

  • 5. Lipid-lowering therapies for cardiovascular disease prevention and management in primary care: PEER umbrella systematic review of systematic reviews.
    Dugré N; Lindblad AJ; Perry D; Allan GM; Braschi É; Falk J; Froentjes L; Garrison SR; Kirkwood JEM; Korownyk CS; McCormack JP; Moe SS; Paige A; Potter J; Thomas BS; Ton J; Young J; Weresch J; Kolber MR
    Can Fam Physician; 2023 Oct; 69(10):701-711. PubMed ID: 37833094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inter-Individual Variability in Lipid Response: A Narrative Review.
    Patnaik S; Pollevick ME; Lara-Breitinger KM; Stone NJ
    Am J Med; 2022 Dec; 135(12):1427-1433.e7. PubMed ID: 35878687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Inhibitors of PCSK9].
    Petrova-Slater I; Denegri A; Pasotti E; Rossi MG; Spirk D; Riesen WF; Moccetti T; Moccetti M
    Rev Med Suisse; 2017 Apr; 13(558):821-825. PubMed ID: 28727332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined lipid-lowering therapy.
    Karásek D
    Vnitr Lek; 2019; 64(12):1177-1184. PubMed ID: 30704254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Lipid Lowering Drugs on Arterial Stiffness: One More Way to Reduce Cardiovascular Risk?
    Reklou A; Katsiki N; Karagiannis A; Athyros V
    Curr Vasc Pharmacol; 2020; 18(1):38-42. PubMed ID: 30663570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LDL-Cholesterol-Lowering Therapy.
    Pirillo A; Norata GD; Catapano AL
    Handb Exp Pharmacol; 2022; 270():73-101. PubMed ID: 32350699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of LDL-C lowering medications and their cardiovascular benefits: Past, present, and future.
    Faluk M; Wardhere A; Mohamoud A; Nor M; Bampastsias D; Oikonomou E; Almubaid Z; Al-Hemyari B
    Curr Probl Cardiol; 2024 Jul; 49(7):102637. PubMed ID: 38735347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Up to date lipid lowering treatment].
    Paragh G; Karádi I
    Orv Hetil; 2016 Jul; 157(31):1219-23. PubMed ID: 27476517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid-lowering therapy: Guidelines to precision medicine.
    Su X; Cheng Y; Chang D
    Clin Chim Acta; 2021 Mar; 514():66-73. PubMed ID: 33359059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.
    Hao Q; Aertgeerts B; Guyatt G; Bekkering GE; Vandvik PO; Khan SU; Rodondi N; Jackson R; Reny JL; Al Ansary L; Van Driel M; Assendelft WJJ; Agoritsas T; Spencer F; Siemieniuk RAC; Lytvyn L; Heen AF; Zhao Q; Riaz IB; Ramaekers D; Okwen PM; Zhu Y; Dawson A; Ovidiu MC; Vanbrabant W; Li S; Delvaux N
    BMJ; 2022 May; 377():e069066. PubMed ID: 35508320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
    Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-inflammatory effects of non-statin low-density lipoprotein cholesterol-lowering drugs: an unused potential?
    Hovland A; Retterstøl K; Mollnes TE; Halvorsen B; Aukrust P; Lappegård KT
    Scand Cardiovasc J; 2020 Oct; 54(5):274-279. PubMed ID: 32500743
    [No Abstract]   [Full Text] [Related]  

  • 17. Nonstatin therapies for management of dyslipidemia: a review.
    Sando KR; Knight M
    Clin Ther; 2015 Oct; 37(10):2153-79. PubMed ID: 26412799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials.
    Koskinas KC; Siontis GCM; Piccolo R; Mavridis D; Räber L; Mach F; Windecker S
    Eur Heart J; 2018 Apr; 39(14):1172-1180. PubMed ID: 29069377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Modern lipid-lowering drugs-A means to counter the problem of undertreatment?].
    Katzmann JL; Laufs U
    Inn Med (Heidelb); 2022 Dec; 63(12):1316-1322. PubMed ID: 35391570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.